Your browser doesn't support javascript.
loading
Evaluation of the IgG antibody response to SARS CoV-2 infection and performance of a lateral flow immunoassay: cross-sectional and longitudinal analysis over 11 months.
Robertson, Louise J; Moore, Julie S; Blighe, Kevin; Ng, Kok Yew; Quinn, Nigel; Jennings, Fergal; Warnock, Gary; Sharpe, Peter; Clarke, Mark; Maguire, Kathryn; Rainey, Sharon; Price, Ruth K; Burns, William P; Kowalczyk, Amanda M; Awuah, Agnes; McNamee, Sara E; Wallace, Gayle E; Hunter, David; Sager, Steve; Chao Shern, Connie; Nesbit, M Andrew; McLaughlin, James A D; Moore, Tara.
Afiliação
  • Robertson LJ; Biomedical Sciences Research Institute, Ulster University, Coleraine, UK.
  • Moore JS; Biomedical Sciences Research Institute, Ulster University, Coleraine, UK.
  • Blighe K; Biomedical Sciences Research Institute, Ulster University, Coleraine, UK.
  • Ng KY; Nanotechnology and Integrated Bioengineering Centre, Ulster University-Jordanstown Campus, Newtownabbey, UK.
  • Quinn N; Clinical Biochemistry Laboratory, Southern Health and Social Care Trust, Portadown, UK.
  • Jennings F; Clinical Biochemistry Laboratory, Southern Health and Social Care Trust, Portadown, UK.
  • Warnock G; Microbiology Laboratory, Southern Health and Social Care Trust, Portadown, UK.
  • Sharpe P; Clinical Biochemistry Laboratory, Southern Health and Social Care Trust, Portadown, UK.
  • Clarke M; Northern Ireland Blood Transfusion Service, Belfast City Hospital, Belfast, UK.
  • Maguire K; Northern Ireland Blood Transfusion Service, Belfast City Hospital, Belfast, UK.
  • Rainey S; Northern Ireland Blood Transfusion Service, Belfast City Hospital, Belfast, UK.
  • Price RK; Biomedical Sciences Research Institute, Ulster University, Coleraine, UK.
  • Burns WP; Nanotechnology and Integrated Bioengineering Centre, Ulster University-Jordanstown Campus, Newtownabbey, UK.
  • Kowalczyk AM; Biomedical Sciences Research Institute, Ulster University, Coleraine, UK.
  • Awuah A; Biomedical Sciences Research Institute, Ulster University, Coleraine, UK.
  • McNamee SE; Nanotechnology and Integrated Bioengineering Centre, Ulster University-Jordanstown Campus, Newtownabbey, UK.
  • Wallace GE; Royal Victoria Hospital, Belfast Health and Social Care Trust, Belfast, UK.
  • Hunter D; Royal Victoria Hospital, Belfast Health and Social Care Trust, Belfast, UK.
  • Sager S; Biomedical Sciences Research Institute, Ulster University, Coleraine, UK.
  • Chao Shern C; R&D, Avellino Labs USA, Menlo Park, California, USA.
  • Nesbit MA; Biomedical Sciences Research Institute, Ulster University, Coleraine, UK.
  • McLaughlin JAD; Nanotechnology and Integrated Bioengineering Centre, Ulster University-Jordanstown Campus, Newtownabbey, UK.
  • Moore T; Biomedical Sciences Research Institute, Ulster University, Coleraine, UK tara.moore@ulster.ac.uk.
BMJ Open ; 11(6): e048142, 2021 06 29.
Article em En | MEDLINE | ID: mdl-34187827
OBJECTIVE: To evaluate the dynamics and longevity of the humoral immune response to SARS-CoV-2 infection and assess the performance of professional use of the UK-RTC AbC-19 Rapid Test lateral flow immunoassay (LFIA) for the target condition of SARS-CoV-2 spike protein IgG antibodies. DESIGN: Nationwide serological study. SETTING: Northern Ireland, UK, May 2020-February 2021. PARTICIPANTS: Plasma samples were collected from a diverse cohort of individuals from the general public (n=279), Northern Ireland healthcare workers (n=195), pre-pandemic blood donations and research studies (n=223) and through a convalescent plasma programme (n=183). Plasma donors (n=101) were followed with sequential samples over 11 months post-symptom onset. MAIN OUTCOME MEASURES: SARS-CoV-2 antibody levels in plasma samples using Roche Elecsys Anti-SARS-CoV-2 IgG/IgA/IgM, Abbott SARS-CoV-2 IgG and EuroImmun IgG SARS-CoV-2 ELISA immunoassays over time. UK-RTC AbC-19 LFIA sensitivity and specificity, estimated using a three-reference standard system to establish a characterised panel of 330 positive and 488 negative SARS-CoV-2 IgG samples. RESULTS: We detected persistence of SARS-CoV-2 IgG antibodies for up to 10 months post-infection, across a minimum of two laboratory immunoassays. On the known positive cohort, the UK-RTC AbC-19 LFIA showed a sensitivity of 97.58% (95.28% to 98.95%) and on known negatives, showed specificity of 99.59% (98.53 % to 99.95%). CONCLUSIONS: Through comprehensive analysis of a cohort of pre-pandemic and pandemic individuals, we show detectable levels of IgG antibodies, lasting over 46 weeks when assessed by EuroImmun ELISA, providing insight to antibody levels at later time points post-infection. We show good laboratory validation performance metrics for the AbC-19 rapid test for SARS-CoV-2 spike protein IgG antibody detection in a laboratory-based setting.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imunoglobulina G / COVID-19 Tipo de estudo: Diagnostic_studies / Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Humans País/Região como assunto: Europa Idioma: En Revista: BMJ Open Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imunoglobulina G / COVID-19 Tipo de estudo: Diagnostic_studies / Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Humans País/Região como assunto: Europa Idioma: En Revista: BMJ Open Ano de publicação: 2021 Tipo de documento: Article